Purified Cynomolgus Monkey OX40 Protein (C-Fc) on SDS-PAGE under reducing (P+) and non-reducing (P-) conditions. The purity of the purified protein appears to be greater than 95% based on reducing condition.
Cat #
Size
Price
Quantity
605001
25 ug
$145
605002
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
HEK293
Target Name
OX40, TNFRSF4, OX40L receptor, CD134, ACT35
Species
Cynomolgus monkey
accession number
XP_005545179
Sources
Recombinant Cynomolgus Monkey OX40 (Leu29-Ala216) with C-terminus Fc tag is expressed in 293 cells.
Molecular Weight
This protein has a predicted molecular weight of 46.7 kDa. Under DTT-reducing conditions, the protein migrates at approximately 65 kDa on SDS-PAGE.
Affinity Tag
C-Fc
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
OX40 (also known as CD134) is a costimulatory receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. Upon binding to its ligand OX40L, OX40 signaling promotes the development of long-lasting memory T cells and sustains immune responses. It is primarily expressed on activated T cells and plays a crucial role in enhancing T cell proliferation, survival, and cytokine production.. Because of its central role in modulating immune activation and tolerance, OX40 is an important target for immunotherapy in cancer, autoimmune diseases, and infectious diseases